BPC-157 — 5mg
109.99€
Tirzepatide — 10mg
The dual GIP/GLP-1 agonist that outperformed semaglutide in every head-to-head clinical trial.
189.99€
Prijs per flacon · Excl. btw 189.99€
- In Stock
- Evidence tier: Established
- Format: Lyophilized
- Purity: 99.6%
- Vial size: 10mg
Uitsluitend voor laboratoriumonderzoek. Niet voor gebruik bij mens of dier.
Over Tirzepatide
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has become one of the most studied peptides in modern metabolic research. It simultaneously targets two incretin pathways, making it a subject of intense scientific interest for its role in glucose metabolism and body composition. Researchers continue to investigate its unique dual mechanism, which distinguishes it from single-agonist compounds.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has become one of the most studied peptides in modern metabolic research. It simultaneously targets two incretin pathways, making it a subject of intense scientific interest for its role in glucose metabolism and body composition. Researchers continue to investigate its unique dual mechanism, which distinguishes it from single-agonist compounds.
Tirzepatide is a 39-amino acid acylated peptide with a C20 fatty diacid moiety enabling once-weekly dosing. It acts as an imbalanced dual agonist: full potency at the GIP receptor (equal affinity to native GIP) and approximately 5-fold weaker affinity at the GLP-1 receptor vs native GLP-1. This imbalanced pharmacology drives unique signaling bias. Activates cAMP accumulation through both GIPR and GLP-1R, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing food intake via central appetite circuits.
Duidelijkheid van het mechanisme: Well-characterized
Tags
Belangrijkste punten
-
Onderzoeksscore 10/10
5,000+ gepubliceerde studies in de dataset
-
Bewijsniveau: Established
Established — Robust Phase 3 data (SURPASS 1-5, SURMOUNT 1-4), FDA-approved as Mounjaro (T2D) and Zepbound (obesity). Thousands of participants across RCTs.
-
Gegevens bij mensen
Large RCTs (thousands of participants)
Opslag en hantering
Gevriesdroogd poeder: Room temp or refrigerated
Na reconstitutie: Refrigerate, use within 30 days
Reconstitutiestappen uit de dataset
- Clean. Remove flip-top cap from tirzepatide vial and swab rubber stopper with alcohol.
- Draw water. Draw 2mL of bacteriostatic water into syringe.
- Inject water. Insert needle through stopper and slowly inject water down the side of the vial. Do not spray directly onto powder.
- Dissolve. Gently swirl (do not shake) until fully dissolved. Solution should be clear.
- Label. Label vial with date and concentration (5mg/mL). Refrigerate immediately.
- Dose. For 2.5mg dose: draw 0.5mL (50 units). For 5mg dose: draw 1.0mL (100 units). Inject subcutaneously once weekly.
Veiligheid en beperkingen
Onderzocht voor: Weight loss, Type 2 diabetes, Metabolic syndrome, Appetite suppression, Body recomposition
Gemelde aanvang: 1-2 weeks for appetite suppression; 4-8 weeks for significant weight loss
Gemelde duur: Ongoing; dose escalation over 4-week intervals from 2.5mg to 15mg
Meldingen uit de community: Nausea common in first 2-4 weeks at each dose escalation, usually subsides. Most users report 1-2 lbs/week loss. Weight regain documented in 82% upon cessation.
For research and educational use only. Source values are reproduced from the current PeptidesEuro content dataset and are not medical advice.
Kwaliteit en specificaties
Product details
- Productcode
- L-TIRZ-10
- Beschikbaarheid
- In Stock
- Evidence tier
- Established
- Format
- Lyophilized
- Purity
- 99.6%
- Vial size
- 10mg
Reconstitutiereferentie
- Bacteriostatisch water
- 2 mL
- Concentratie
- 5mg/mL when reconstituted with 2mL. 2.5mg dose = 0.5mL (50 units on insulin syringe).
- Spuit
- 29-31G insulin syringe
Onderzoeksparameters
- Standaardhoeveelheid
- 2500 µg
- Alternatieve hoeveelheid
- 5000 µg
- Flacon
- 10 mg
- Schatting uit de dataset
- 1 vial lasts 4 weeks at 2.5mg/week
Laboratoriumrapport
- Laboratorium
- Janoshik Analytical
- Testdatum
- 2026-03-01
- Document
- Pdf niet bijgevoegd
Bekijk de wetenschap
-
PMID 33325008
Lees de studie: The Role of Tirzepatide in Management of T2D: SURPASS Trials (opent in een nieuw tabblad)
The Role of Tirzepatide in Management of T2D: SURPASS Trials
39-amino acid synthetic peptide; dose-dependent weight loss up to 12.4%
-
PMID 36050763
Lees de studie: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for T2D (opent in een nieuw tabblad)
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for T2D
First dual agonist approved; superior HbA1c and weight reduction vs semaglutide
-
PMID 37385275
Lees de studie: Tirzepatide for obesity in adults without diabetes (opent in een nieuw tabblad)
Tirzepatide for obesity in adults without diabetes
Up to 22.5% body weight loss at 15mg dose over 72 weeks
Studies worden ter referentie vermeld. De meeste zijn uitgevoerd in dier- of celmodellen; de resultaten tonen geen veiligheid of werking bij mensen aan.
Verder lezen
Community evidence
- Source window English Reddit Updated 13 Aug 2026 · 2-year window
- Coverage confidence Low Confidence in the available community sample
- Distribution Pending Not enough data for a distribution.
Selected reports
-
10 months agor/PMDD · Post
tirzepatide … started tirzepatide … ~95% improvement in quality of life
-
6 months agor/TirzepatideRX · Post
I just took my second dose of 5MG and I am starting to drop a few pounds, but I feel miserable! … I was on 2.5MG for a month and I felt fine, but didn't lose any weight.
-
8 months agor/tirzepatidecompound · Post
I have been on compound Semiglutide for a while and I had the WORST nausea, I would get nauseous just drawing up my dose lol so I switched to Tirzepatide and just took my first dose. … I have been on compound Semiglutide for a while and I had the WORST nausea, I would get nauseo…
Based on 5 qualifying reports from 5 threads. 34 candidates excluded as duplicates, promotion, deleted content, or lacking concrete personal experience. Reddit self-reports are not medical evidence or proof of causation.
Vragen over Tirzepatide
Vragen en antwoorden die bij dit product zijn vastgelegd.
Clinical data shows weight regain in approximately 82% of participants after discontinuation. Most researchers view it as an ongoing protocol rather than a short cycle.
Tirzepatide is the active compound. Mounjaro is the brand name for type 2 diabetes, Zepbound for obesity. Research-grade tirzepatide is the same molecule.
Tirzepatide is a dual agonist (GIP + GLP-1) while semaglutide targets only GLP-1. Clinical trials show tirzepatide produces roughly 50% more weight loss. It also tends to have a different side effect profile.
Beoordelingen
Er zijn nog geen beoordelingen voor dit product.
Gerelateerde producten
-
-
MOTS-c — 10mg
189.99€
-
Tirzepatide — 20mg
329.99€
-
Retatrutide — 10mg
289.99€
-
Tesamorelin — 10mg
279.99€
Zo werkt bestellen
Productgegevens, bronnen en je bestelling blijven met elkaar verbonden.
-
Kies de verbinding
Kies een verbinding en flaconmaat in de catalogus.
-
Bekijk de productinformatie
Open de productdetails en het onderliggende onderzoek.
-
Bewaar de bronnen
Bewaar de bronvermeldingen voor je administratie.
Waarom bestellen bij PeptidesEuro
Verbindingsprofielen
Structuur, beschikbare hoeveelheden en hanteringsnotities op één plek.
Studiebronnen
Productpagina's verwijzen naar de studies achter elke verbinding.
Eén bestelhistorie
Bestellingen en hun details blijven in je account.
Duidelijke productgegevens
Prijs, voorraadstatus en btw staan bij elk product.
PeptidesEuro is a research materials supplier operated by Pepticore LLC. We provide high-purity peptides and research compounds for in-vitro laboratory and scientific research purposes. All products are sold strictly for research use only and are not intended for human or animal consumption.
No. All products sold through meimx.com are intended strictly for in-vitro laboratory and scientific research purposes only. They are not intended for human or animal consumption, injection, ingestion, inhalation, or any form of administration to living organisms. By purchasing from PeptidesEuro, you acknowledge and agree to these terms as outlined in our Terms of Service.
No. Our products have not been evaluated, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. They are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. PeptidesEuro is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
No. PeptidesEuro does not provide medical advice, treatment recommendations, or dosing instructions. Any information on our website, including product descriptions and referenced research, is provided for educational and informational purposes only. If you have medical questions, please consult a licensed healthcare provider.
Research Use Only means that our products are sold exclusively as reference standards and research materials for use in laboratory and scientific research settings. Purchasers agree to use all products solely for legitimate research purposes in compliance with all applicable laws and regulations.
Klaar om Tirzepatide te bestellen?
Blader door de catalogus of beantwoord één vraag in de productzoeker.